Action MRK MERCK KGAA
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Merck KGaA

Actions

MRK

DE0006599905

Marché Fermé - Xetra
Autres places de cotation
 17:35:23 15/07/2024 		Varia. 5j. Varia. 1 janv.
151,8 EUR -1,62 % Graphique intraday de Merck KGaA +0,43 % +5,31 %
11/07 Bourse de Francfort : Südzucker subit un fort revers Our Logo
11/07 AVIS D'ANALYSTES DU JOUR : Publicis, Rémy Cointreau, Sanofi, Spie, Ubisoft, Verallia, Vivendi, Alstom... Our Logo

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Merck : MilliporeSigma Announces Non-Binding MoU with Afrigen Biologics for Development of mRNA Vaccine Technology Platform
PU
Merck KGaA: Phase III trials of xevinapant in locally advanced head & neck cancer discontinued
EQ
Merck : Q1 24 Financial Statement
PU
Merck : Q1 24 Earnings Presentation
PU
Merck : Q1 24 Quarterly statement
PU
Caris Life Sciences Announces Partnership with Merck KGaA, Darmstadt, Germany to Discover Novel Cancer Targets and Accelerate First-In-Class Antibody Drug Conjugate Development
AQ
Merck's Corporate Venture M Ventures Arm Backs Nucleai to Advance Its First-in-class Spatial AI Biomarker in Active Clinical Enrollment
AQ
Merck : Prospectus - C-029771
PU
DD: Merck KGaA: Dr. Matthias Heinzel, buy
EQ
DD: Merck KGaA: Peter Guenter, buy
EQ
Merck KGaA, Darmstadt, Germany, Invests More than EUR 300 Million in New Life Science Production Site in Korea
AQ
AFR: Merck KGaA: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
EQ
AFR: Merck KGaA: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements
EQ
Biocytogen Launches RenBiologics, a Sub-Brand Focused on Out-Licensing Fully Human Antibodies for Therapeutic Development
AQ
Inspirna Partners with Merck KGaA, Darmstadt, Germany, to Accelerate Global Development of Ompenaclid
AQ
Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQ
Merck KGaA: Phase III trial results for evobrutinib in relapsing multiple sclerosis did not meet primary endpoint of reducing annualized relapse rates (ARR) compared to oral teriflunomide
EQ
Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQ
Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQ
Veeva European Commercial Summit Gathers Life Sciences Industry Leading the Next Generation of Commercial Excellence
AQ
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action MRK
  4. Actualités Merck KGaA
  5. Communiqués